Thursday, May 9, 2013
Publication and contact
CD44, CD47, c-Met proto-oncogene (MET;
HGFR) and epithelial cell adhesion molecule
as a signature for metastasis-initiating circulating tumor cells (CTCs) in
A protein signature
specific to EpCAM+ CTCs associated with brain metastases could be used
for diagnosis of metastatic breast cancer. EpCAM+ CTCs isolated from individuals with progressive
metastatic breast cancer expressed CD44, CD47 and MET. In immunodeficient
mice, injection of that subset of CTCs resulted in metastasis to the bone. In
blood samples from patients with cancer, increased levels of EpCAM+ CTCs expressing CD44, CD47 and MET correlated with
shorter overall survival. Next steps include genetically examing whether MET
and CD47 are essential for survival and function of metastasis-initiating
cells in hormone receptor-positive breast cancers and testing several MET and
CD47 inhibitors on the newly established CTC lines.
Published online May 9, 2013
Patent application pending;
available for licensing
Baccelli, I. et al. Nat.
Biotechnol.; published online April 21, 2013;
Contact: Andreas Trumpp, Heidelberg Institute for Stem Cell
Technology and Experimental Medicine GmbH, Heidelberg, Germany
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]